Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Measures of mortality in prostatic cancer.

Goodman CM, Ritchie AW, Chisholm GD.

Br J Cancer. 1990 Mar;61(3):465-8.

2.

Predictors of cancer progression in T1a prostate adenocarcinoma.

Cheng L, Bergstralh EJ, Scherer BG, Neumann RM, Blute ML, Zincke H, Bostwick DG.

Cancer. 1999 Mar 15;85(6):1300-4.

PMID:
10189135
3.

[Prognosis of prostate cancer with elevated prostatic acid phosphatase].

Saito T, Kitamura Y, Komatsubara S.

Hinyokika Kiyo. 2006 Mar;52(3):177-80. Japanese.

PMID:
16617869
4.

Rising incidence of prostate cancer in Scotland: increased risk or increased detection?

Brewster DH, Fraser LA, Harris V, Black RJ.

BJU Int. 2000 Mar;85(4):463-72; discussion 472-3.

5.

The prognosis of prostatic cancer in the younger man.

Harrison GS.

Br J Urol. 1983 Jun;55(3):315-20.

PMID:
6850251
6.

Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival.

Bostwick DG, Qian J, Pacelli A, Zincke H, Blute M, Bergstralh EJ, Slezak JM, Cheng L.

J Urol. 2002 Sep;168(3):1204-11.

PMID:
12187268
7.

[Epidemiologic indicators of adenocarcinoma of the prostate. Results on 436 patients].

Arrizabalaga Moreno M, García González JI, Diez Rodríguez JM, Esteban Artiaga R, Castro Pita M, Navarro Sebastian J, Mora Durbán M, Paniagua Andrés P.

Actas Urol Esp. 1997 Oct;21(9):852-61. Spanish. Erratum in: Actas Urol Esp 1997 Nov-Dec;21(10):1032.

PMID:
9471868
8.

Incidental prostatic adenocarcinoma in patients undergoing radical cystoprostatectomy for bladder cancer.

Abbas F, Hochberg D, Civantos F, Soloway M.

Eur Urol. 1996;30(3):322-6.

PMID:
8931964
10.

Impact of race on survival in men with metastatic hormone-refractory prostate cancer.

Halabi S, Small EJ, Vogelzang NJ, Barrier RC Jr, George SL, Gilligan TD.

Urology. 2004 Aug;64(2):212-7.

PMID:
15302462
11.
12.
13.

Prostate cancer incidence and mortality trends among elderly and adult Europeans.

Vercelli M, Quaglia A, Marani E, Parodi S.

Crit Rev Oncol Hematol. 2000 Aug;35(2):133-44.

PMID:
10936470
14.
15.

Three-dimensional conformal therapy versus standard radiation therapy in localized carcinoma of prostate: an update.

Perez CA, Michalski JM, Mansur D, Lockett MA.

Clin Prostate Cancer. 2002 Sep;1(2):97-104.

PMID:
15046700
16.
17.
19.

Biochemical disease-free survival following 125I prostate implantation.

Beyer DC, Priestley JB Jr.

Int J Radiat Oncol Biol Phys. 1997 Feb 1;37(3):559-63.

PMID:
9112453
20.

Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR; CaPSURE Investigators..

Cancer. 2006 Apr 15;106(8):1708-14.

Items per page

Supplemental Content

Support Center